While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In the last year, advances in arthritis treatment include the expansion of two new classes of medications used to treat autoimmune forms of arthritis. This year’s JointHealth™ Arthritis Medications Report Card reflects this change and covers three medication categories – biologic response modifiers, subsequent entry biologics, and targeted small molecule medications – increasing the number of individual arthritis medications evaluated in the Report Card to 13.
In this issue of “What has ACE done for you lately” – a monthly roundup of what we have accomplished and what we are currently working on – we highlight our campaigns in the workplace, healthcare, arthritis community and research.
ACE at the American College of Rheumatology Meeting
Arthritis Consumer Experts (ACE) attended the American College of Rheumatology (ACR) Annual Meeting in Boston in November. ACE networked with rheumatologists, researchers, healthcare professionals, patient organization and patients living with arthritis to understand the future of arthritis treatment and the promises they may hold for people living with the disease. Continue reading
The Common Drug Review (CDR) is now welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (the medication’s generic name) for the treatment of moderate to severe plaque psoriasis. This medication has not yet been approved for use by Health Canada and therefore does not have a brand name. However, the Common Drug Review, in an effort to speed up the review process, is calling for patient input prior to Health Canada’s approval. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. In two phase III clinical trials, it has been shown to be effective and well tolerated for treating plaque psoriasis. Continue reading
Toujours à la recherche de façons d’améliorer la satisfaction de notre clientèle arthritique, le comité ACE (Arthritis Consumer Experts) effectue chaque année des sondages sur le degré de satisfaction et d’intérêt envers les programmes JointHealth™. Et cette année n’a pas fait exception. Grâce à votre précieuse collaboration, nous avons été en mesure d’apprendre ce dont vous avez besoin et ce que vous attendez du comité ACE et de la série de programmes JointHealth™.
Aux nombreuses personnes de partout au Canada qui ont pris le temps de répondre au sondage, merci infiniment ! Dans ce numéro du Mensuel JointHealth™, nous traiterons des résultats de ce sondage.
Nous traiterons également de notre réponse à certains commentaires de nos abonnés, de personnes atteintes d’arthrite, de professionnels de la santé et de décideurs.
The Canadian Institute for the Relief of Pain and Disability (CIRPD), in collaboration with Work: A Journal of Prevention, Assessment and Rehabilitation, will be hosting a free webinar tomorrow at 11:00am PST, 2:00pm EST. The Manager Involvement in Work Re-Integration webinar will feature Dr. Karin Maiwald, who will be presenting a study into the managers’ experiences with return-to-work policy in a Canadian setting. Continue reading
Always on the lookout for ways to improve arthritis consumer satisfaction, each year Arthritis Consumer Experts (ACE) runs JointHealth™ Program Satisfaction and Interest surveys. This year was no different. From your valuable input, we learned what you want and need from ACE and its JointHealth™ suite of programs.
To the many people from all over Canada who filled out the survey, thank you! In this issue of JointHealth™ monthly, we discuss the results of that survey.
We also highlight our response to selected feedback from our subscribers, including people living with arthritis, healthcare professionals, and decision-makers.